important not only for B-cell differentiation but also for T-cell maturation and the development of T-cell leukemia. The presence of BCL11A XL protein in normal and malignant T cells is therefore not inconsistent with these findings. Indeed, the presence of BCL11A XL in the nuclei of thymic epithelial cells may be of importance as interactions between the thymocyte and epithelial cell compartments play a vital role in T-cell development and selection.
In conclusion, this is the first description of BCL11A XL protein distribution in both normal and neoplastic cells. Besides representing a transcription factor that is differentially expressed in B-cell development, BCL11A XL is an additional marker for pDCs. The antibody described here represents an important tool for ascertaining the function of BCL11A XL not only in normal cellular development but also the role of BCL11A and/or its interacting proteins in tumorigenesis.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects Leukemia (2006) Among the biological prognostic factors so far identified in chronic lymphocytic leukemia (CLL), mutation or deletion of the p53 gene encoded at 17p13 is the most powerful predictor of short survival. p53 is a transcription factor that is activated by DNA damage and coordinates the cellular response to such damage by triggering apoptosis or cell-cycle arrest. In doing so, it fulfils an important function in regulating cell growth and survival in the face of cellular stresses and plays a pivotal role in Denotes very weak labeling of the tumor cells.
Letter to the Editor maintaining genomic integrity. In keeping with this, p53 is inactivated in about half of all human cancers, the usual defect being mutation of one allele and deletion of the other. 1 p53 defects are rare among patients with newly diagnosed CLL, but are more prevalent among patients with advanced disease. 2 In keeping with the fact that p53-mediated apoptosis underpins the cytotoxicity of many anticancer drugs, 3 p53 defects in CLL have been strongly linked to resistance to alkylating agents and purine analogs in ex vivo experiments, in retrospective clinical studies and most importantly in three large prospective clinical trials of first-line chemotherapy. In the German CLL4 trial comparing F with FC (ref 4), p53 deletion was found to be the most powerful predictor of therapeutic resistance and short progression-free survival, and the only predictor of short survival (median 15.9 months) in multivariate analysis (Stilgenbauer et Glucocorticoids are of interest in this context as they kill lymphoid cells by p53-independent apoptosis. At the clinical level, high-dose methylprednisolone (HDMP) produced an overall response rate of 77% in a cohort of 25 patients with advanced refractory CLL. 5 Responders included five out of 10 patients with p53 defects, two of whom achieved a nodular PR. Importantly, HDMP was effective at inducing regression of bulky lymphadenopathy.
Monoclonal antibodies are also of potential interest in the treatment of p53-deleted CLL as their cytotoxicity is predominantly mediated by complement-mediated cell lysis and antibody-dependent cell-mediated cytotoxicity, neither of which should involve the p53 pathway. In keeping with these theoretical considerations, alemtuzumab induced a complete response in a patient with chemo-resistant p53-deleted CLL, 6 and emerging data from the German CLL2H trial of alemtuzumab in fludarabine-refractory CLL indicate that response and progression-free survival are unaffected by p53 deletion status (Stilgenbauer et al. Blood, 2004 ; 104: 140a; abstract 478). The overall response rate to alemtuzumab among previously treated patients with p53 defects appears to be in the order of about 50%, with most responses being partial. 7, 8 Although alemtuzumab is effective at eradicating detectable CLL from the blood and bone marrow, it is ineffective in patients with substantial lymph node enlargement. This consideration very much limits the usefulness of alemtuzumab monotherapy in CLL patients with p53 defects, as lymphadenopathy is common among such cases.
In an attempt to overcome the limitations of alemtuzumab or HDMP monotherapy in p53-deleted CLL, a protocol was developed in which the two agents are given in combination. The regimen consists of up to four 28-day cycles. Each cycle consists of intravenous methylprednisolone 1.0 g/m 2 days 1-5 and alemtuzumab 30 mg thrice weekly days 1-28 after an initial week of dose escalation. Alemtuzumab is given via the intravenous route during cycle 1 to ensure that therapeutic plasma levels were achieved quickly, and via the subcutaneous route thereafter. Paracetamol and chlorpheniramine are administered before each dose of alemtuzumab to reduce the risk of allergic reactions. Patients undergo weekly surveillance for cytomegalovirus (CMV) reactivation and receive lansoprazole, allopurinol and antimicrobial prophylaxis with co-trimoxazole, aciclovir and fluconazole or itraconazole throughout the treatment period. Granulocyte-colony stimulating factor (G-CSF) and ciprofloxacin are administered if the neutrophil count falls below 1.0 Â 10 9 /l. The CAM-PRED regimen was designed to be concurrent rather than sequential in order to exploit any mechanistic synergy between the two drugs. It was also designed to be intensive in order to achieve maximal cytoreduction as quickly as possible. This was felt to be important owing to the pivotal role of p53 in maintaining genomic integrity and the consequent risk that exposing p53-defective CLL cells to suboptimal drug concentrations might lead to the emergence of resistant clones. The protocol is therefore tailored to patients with p53 defects not only in terms of the choice of drugs but also in terms of scheduling and route of administration.
Data are available on five patients with p53 defects who were treated with the regimen during the development of a formal phase II clinical trial. All had clinically aggressive CLL with bulky lymphadenopathy. Patients were offered CAM-PRED on the grounds that they were unlikely to achieve a good and sustained response with conventional chemotherapy, alemtuzumab monotherapy or HDMP monotherapy. Each case was subjected to specialist peer review before starting treatment, and the advantages and disadvantages of each treatment option were discussed in detail with patients and their families. Retrospective permission to publish the findings was obtained from the Liverpool Adult Research Ethics Committee.
A summary of baseline patient characteristics is shown in Table 1 . The patients were all male with a median age of 56 years (range 48-73). Two patients were previously untreated, whereas the remainder had received a median of three lines of prior therapy (range 3-6), which included autologous stem-cell transplantation, allogeneic stem-cell transplantation and single agent alemtuzumab. Prior medical problems were numerous. One patient (case 1) had a history of autoimmune haemolytic anaemia, recurrent venous thrombo-embolism, bacterial pneumonia, polyoma virus cystitis and cytomegalovirus pneumonitis. Another (case 3) had a history of leukaemic meningitis, graftversus-host disease (GVHD), respiratory syncytial virus pneumonitis and Pneumocysitis carinii pneumonia. At the time of treatment, three patients were Binet stage B and the remainder stage C. All had substantial lymphadenopathy and p53 abnormalities. The latter consisted of gene deletion affecting at least 20% of leukaemia cells in four cases, protein overexpression in four cases and functional impairment in three cases. Four patients (all except case 3) had a p53 gene deletion plus at least one other type of p53 defect in keeping with the remaining allele being mutated. p53 deletion and functional analysis could not be performed on case 3 as this patient relapsed with lymphadenopathy only and fresh material could not be obtained. However, immunohistochemical staining of fixed biopsy tissue showed unequivocal overexpression of p53 protein indicative of gene mutation.
The therapeutic response to CAM-PRED is shown in Table 2 . Patients were assessed for response during and at completion of treatment based on clinical examination, blood count, computed tomography (CT) scanning and bone marrow assessment. Responses were graded according to National Cancer Institute criteria. In four patients (all except case 1), bone marrow was assessed for MRD by flow cytometry. All patients received at least one cycle of treatment (median 3, range 1-5). One patient (case 5) received a fifth cycle of treatment as he was tolerating it well and continuing to respond after four cycles. Scheduling delays were encountered in three patients (cases 2, 3 and 4) owing to infective problems. Treatment was discontinued in patient 3 after only one cycle as he was found to have achieved an MRD-negative complete response (CR), and after two cycles in patient 1 owing to a severe bacterial chest infection. Patient 4 received 16 weeks of alemtuzumab, but the fourth cycle of HDMP was omitted as his nodal disease had regressed after cycle 3 and he had experienced infective problems while receiving combination therapy. All five patients responded to therapy. Three patients achieved a CR, one an nPR, and one a partial response (PR). Two of the three patients who achieved a CR (cases 2 and 3) were also found to have no evidence of disease in the bone marrow by four-colour flow cytometry. The other patient who achieved a CR (case 5) was found to be MRD positive in the marrow at a level of 0.01%. Two of the three patients who achieved a CR (cases 2 and 5) showed no signs of progression at their latest follow-up 12 and 8 months after completion of therapy, whereas patient 3 developed a deep vein thrombosis 12 months after completing therapy and has just been found to have recurrent lymphadenopathy. The two patients who achieved a PR (case 1) or nPR (case 4) progressed at 4 and 6 months, respectively, following completion of therapy. Patient 1 developed recurrence of his bulky lymphadenopathy and received a further 3 months of CAM-PRED with minimal toxicity. Although he initially underwent a further partial response, he then progressed through treatment with a Richter transformation. He failed to respond to R-CHOP and died of neutropenic sepsis. Patient 4 progressed in the bone marrow, responded to further alemtuzumab monotherapy and then underwent an unrelated donor allogeneic haemopoietic stem-cell transplant. However, he relapsed early post-transplant with heavy marrow involvement and died of neutropenic sepsis.
The toxicity associated with CAM-PRED is summarized in Table 3 . All five patients experienced infective problems during treatment, including CMV reactivation, radiologically suspected pulmonary aspergillosis, bacterial chest infections and bacterial sinusitis. All infections resolved with appropriate treatment. It should be noted that four of the five patients in this series (all except case 5) were at very high risk of infection by virtue of being heavily pre-treated or having a history of prior infective problems (see Table 1 ). Haemopoietic toxicity was transient and modest with a median haemoglobin nadir of 8.6 g/dl (range 8.4-10.2), a median platelet nadir of 85 Â 10 9 /l (range 11-116) and a median neutrophil nadir of 0.5 Â 10 9 /l (range 0.4-1.3). The CD4 count showed signs of recovery after completion of treatment in each of the three patients in whom it was measured, reaching a level of 100 Â 10 6 /l at between 2 and 6 months. Patient 5 had several respiratory infections following completion of therapy, but he responded well to oral antibiotics and remains in good health. Patient 2 developed cryptogenic organizing pneumonia 9 months post-treatment, but this resolved promptly with oral prednisolone and he is also currently very well.
Apart from alemtuzumab and glucocorticoids, the only other drug with proven activity in p53-defective CLL at the present time is flavopiridol. However, the agent is notorious for causing an extreme form of tumour lysis syndrome among patients with a high lymphocyte count and is not yet widely available.
Emerging data from the German CLL3X trial indicate that reduced-intensity conditioning allogeneic stem-cell transplantation has a low transplant-related mortality and a low relapse rate of about 25%. Importantly, outcome seems to be unaffected by p53 status, indicating that the graft-versus leukaemia effect does not involve the p53 pathway. In present series of five cases treated with CAM-PRED, only one patient was subsequently transplanted (case 4). Patient 1 opted against transplantation in view of his age, lack of an HLA-matched sibling donor and history of infective problems. Patient 2, who achieved an MRDnegative CR, also opted against transplantation in favour of regular MRD monitoring with a view to early intervention with alemtuzumab monotherapy at the first sign of relapse. Patient 3, who also achieved an MRD-negative CR, had relapsed after a prior allogeneic stem-cell transplant. A decision was made not to consolidate his response to CAM-PRED with a donor leucocyte infusion owing to his history of chronic graft-versushost disease. Patient 5, who achieved an MRD-positive CR, was considered too old for allogeneic transplantation and has also opted for an MRD-monitoring approach.
In summary, the CAM-PRED regimen appears to be a highly effective treatment option for CLL patients with p53 defects, particularly in previously untreated patients. Toxicity is significant but appears to be manageable with appropriate antimicrobial prophylaxis and surveillance. The regimen will be evaluated more thoroughly within the NCRI UKCLL06 trial, but in the meantime it is hoped that these promising initial findings will stimulate a change in paradigm towards a more tailored approach to first-line therapy based on routine biological risk Deregulation of the DNA-methylating machinery is associated with neoplastic transformation of many types of cells in humans. Both general genomic hypomethylation and regional hypermethylation coexist in DNA extracted from different types of neoplastic tissues. A number of studies have sought to reconcile this apparent paradox, suggesting that in solid cancers, the high frequency of DNA hypomethylation, the nature of the affected sequences and the absence of associations with DNA hypermethylation are consistent with an independent role of DNA undermethylation in the development of these solid neoplasms.
1,2
We have recently shown that the methylation of cytosine nucleotides in acute lymphoblastic leukemia (ALL) cells is the most important way to inactivate cancer-related genes in this disease. In fact, this epigenetic event can help to inactivate tumor-suppressive apoptotic or growth-arresting responses and has prognostic impact in B-and T-ALL. 3, 4 The presence in individual tumors of multiple genes simultaneously methylated (a condition termed CpG island methylator phenotype or CIMP þ ) is an independent factor of poor prognosis in both childhood and adult ALL in terms of disease-free survival (DFS) and overall survival (OS). However, no studies have addressed the role of hypomethylation in lymphoid leukemogenesis and therefore, it is unclear whether these epigenetic changes are causally linked, or are distinct and biologically unrelated phenomena.
In the present study, we analyzed the extent of both DNA hypomethylation and hypermethylation in 307 consecutive patients (179 men; 128 women) who were diagnosed with de novo ALL between January 1989 and December 2004 (median age at diagnosis in the study population as a
